Stockholm- Uppsala, a popular investment region for Life Science
Over the last year, Stockholm-Uppsala Life Science companies have received several big investments. Cancer diagnostics, protein production and stem cell matrices are some examples of what attracts big international investments. The one common denominator for these investments is that all of the companies are on the Life Science Hotlist, a list of the hottest life science companies in the region.
This year, four Hotlist companies have received a total of five investments. The four companies in the Stockholm area are Biolamina, Xbrane, Biovica and Biochromix.
Xbrane Bioscience has signed an agreement with an Indian company in helping them to develop a bacterial system for protein production. Cadila Pharmaceuticals Limited, one of India's leading pharmaceutical research companies, has purchased Sweden's BioChromix NewCo, a developer of new and innovative treatments for protein misfolding diseases. Biovica has started collaboration with an American cancer institute. In their joint effort, Biovica’s serum biomarkers will be used to predict outcomes and monitor therapeutic effects in patients with lung cancer.
Biolamina has entered into two agreements, one of which is a global distribution agreement for their stem cell matrices.
- We are very pleased with these successful investments and are proud of the fantastic companies we have here in the Stockholm-Uppsala region, says Ylva Hultman, Business Development Manager at Stockholm Business Region Development. We have already achieved our goal for the year. The area's life science companies are very popular internationally right now and we have a long and unique tradition of research that emphasizes that this is not some flash in the pan.
- Being one of the Hotlist companies has been very important for Biovica. It has put us in contact with many potential customers and investors. Thanks to this, we are seeing our products included in more and more projects with pharmaceutical companies and researchers, who are developing new and improved drugs for cancer. As a direct result of the Hotlist, we are involved in a cancer study with a very well-reputed, American cancer institute and a large, multinational, pharmaceutical company, says Anders Rylander, CEO of Biovica.
The Life Science Investment Hotlist functions as a tool for investors, and by creating awareness of these companies, joint projects and other collaborations are fostered. To qualify for the list, the company must offer a product or service with global potential.
See the Investment Hotlist in its entirety:
www.investstockholm.com/en/Life-Science-Hotlist
The companies include:
xbrane.com
biochromix.com
biolamina.com
biovica.com
Sabina von Greyerz, Public Relations Manager, Stockholm Business Region
Phone: 46850828069
e-mail: sabina.von.greyerz@stockholm.se
Tags: